作为阿尔茨海默病候选药物的西尔德纳菲尔:真实世界患者数据观察和来自患者诱导的多能干细胞衍生神经元的机械观察
Dhruv Gohel1, Pengyue Zhang2, Amit Kumar Gupta1
1Genomic Medicine Institute,Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Journal of Alzheimer's disease : JAD
|March 1, 2024
概括
西尔德纳菲尔在降低阿尔茨海默病 (AD) 风险和病理学方面表现有前途. 现实世界的数据和来自患者的神经元表明,西尔德纳菲尔是阿尔茨海默病的潜在治疗药物,尽管需要进行临床试验.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学是一种遗传学.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,急需治疗.
- 作为固酶-5抑制剂的西尔德纳菲尔正在研究其在阿尔茨海默病中的潜在治疗作用.
研究的目的:
- 调查西尔代纳菲尔在阿尔茨海默病中的潜在治疗益处.
- 分析现实世界患者数据,并评估西尔代纳菲尔在阿尔茨海默病中的作用机制.
主要方法:
- 来自MarketScan®和Clinformatics®数据库的真实世界患者数据分析.
- 倾向性得分分层分析,调整混因素.
- 使用家族性和零星性阿尔茨海默病患者衍生的诱导多能干细胞 (iPSC) 神经元评估西尔德纳菲尔的机制.
主要成果:
- 在四种药物队列中,西尔德纳菲尔使用与阿尔茨海默病的可能性降低有关.
- 与螺旋龙相比,西尔代纳菲尔显著降低了AD发病率 (54%) 和流行率 (30%).
- 西尔德纳菲尔治疗剂量取决于降低陶过酸化和向与AD相关的基因和途径在iPSC衍生的神经元.
结论:
- 现实世界的数据和机制研究支持西尔德纳菲尔作为阿尔茨海默病的潜在重新用途药物.
- 需要进一步的随机临床试验来证实西尔代纳菲尔在阿尔茨海默病中的因果治疗作用.
相关概念视频
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188


